1
|
Deconinck E, Raimondo M, Borioni A, Grange Y, Rebière H, Mihailova A, Bøyum O, Maurin JK, Pioruńska-Sędłak K, Olsen LS, Acevska J, Brezovska K, Rundlöf T, Portela MJ, Meieranz S, Miquel M, Bertrand M. Clustering of Tadalafil API Samples According to their Manufacturer in the Context of API Falsification Detection. J Pharm Sci 2023; 112:2834-2842. [PMID: 37220827 DOI: 10.1016/j.xphs.2023.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/17/2023] [Accepted: 05/17/2023] [Indexed: 05/25/2023]
Abstract
This paper reports the results of the active pharmaceutical ingredient (API) fingerprint study, organised by the General European Official Medicines Control Laboratory Network (GEON), on tadalafil. A classical market surveillance study, evaluating compliance to the European Pharmacopoeia, was combined with a fingerprint study, the latter to obtain characteristic data for the different manufacturers, allowing the network laboratories to conduct authenticity tests for future samples, as well as to detect substandard and falsified samples. In total, 46 tadalafil API samples from 13 different manufacturers were collected. For all samples fingerprint data was collected through analysis of impurities and residual solvents, mass spectrometric screening, X-ray powder diffraction and proton nuclear magnetic resonance (1H-NMR). Chemometric analysis revealed that all manufacturers could be characterised based on the impurity, residual solvent and 1H-NMR data. Future suspicious samples in the network will therefore be analysed with these techniques in order to attribute the sample to one of the manufacturers. If the sample cannot be attributed, a more profound investigation will be necessary to reveal the origin of the sample. In cases where the suspect sample is claimed to be from one of the manufacturers included in this study, analysis can be limited to the test distinguishing that manufacturer.
Collapse
Affiliation(s)
- E Deconinck
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050, Brussels, Belgium.
| | - M Raimondo
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, viale Regina Elena 299, 00161, Rome, Italy
| | - A Borioni
- Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, viale Regina Elena 299, 00161, Rome, Italy
| | - Y Grange
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; French National Agency for Medicines and Health Products Safety (ANSM), Laboratory Controls Division, 635 Rue de la Garenne, F-34740, Vendargues, France
| | - H Rebière
- French National Agency for Medicines and Health Products Safety (ANSM), Laboratory Controls Division, 635 Rue de la Garenne, F-34740, Vendargues, France
| | - A Mihailova
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - O Bøyum
- Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - J K Maurin
- National Medicines Institute, 30/34 Chelmska str., 00-725, Warsaw, Poland
| | - K Pioruńska-Sędłak
- National Medicines Institute, 30/34 Chelmska str., 00-725, Warsaw, Poland
| | - L Stengelshøj Olsen
- Danish Medicines Agency, Medicines Control and Inspection Division, Axel Heides Gade 1, 2300, Copenhagen S, Denmark
| | - J Acevska
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North Macedonia
| | - K Brezovska
- Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North Macedonia
| | - T Rundlöf
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Swedish Medical Products Agency, Laboratory, Box 26, Dag Hammarskjölds väg 42, SE-751 03, Uppsala, Sweden
| | - M J Portela
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. Parque de Saúde de Lisboa - Avenida do Brasil, 53, 1749-004, Lisboa, Portugal
| | - S Meieranz
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Landeslabor Berlin-Brandenburg - Institut für Lebensmittel, Arzneimittel, Tierseuchen und Umwelt, Rudower Chaussee 39, 12489, Berlin, Germany
| | - M Miquel
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France
| | - M Bertrand
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France
| |
Collapse
|
2
|
Rebiere H, Grange Y, Deconinck E, Courselle P, Acevska J, Brezovska K, Maurin J, Rundlöf T, Portela MJ, Olsen LS, Offerlé C, Bertrand M. European fingerprint study on omeprazole drug substances using a multi analytical approach and chemometrics as a tool for the discrimination of manufacturing sources. J Pharm Biomed Anal 2022; 208:114444. [PMID: 34773838 DOI: 10.1016/j.jpba.2021.114444] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 10/14/2021] [Accepted: 10/24/2021] [Indexed: 11/29/2022]
Abstract
Like drug products, Active Pharmaceutical Ingredients (APIs) are subject to substandard and falsification issues, which represent a threat to patient health. In order to monitor the quality of drug substances and prevent the use of non-compliant APIs, Official Medicine Control Laboratories work together in a European network developing coordinated strategies and programmes. The API working group proposed a market surveillance study on omeprazole and omeprazole magnesium with the objectives of controlling the pharmaceutical quality of samples, checking compliance with the monographs of the European Pharmacopoeia, and collecting analytical fingerprints that could be further used to differentiate manufacturing sources for future authenticity investigations. The study described in this article reports the analysis carried out by 7 European laboratories on 28 samples from 11 manufacturers with 5 analytical techniques (related substances with HPLC, residual solvents with GC-MS, near infrared spectroscopy, proton nuclear magnetic resonance spectroscopy and X-ray powder diffractometry). The large amount of resulting analytical data were centralized and treated with two chemometric methods: Principal Component Analysis and Hierarchical Clustering Analysis. Data were analyzed separately and in combination (data fusion), allowing us to conclude that NMR and XRPD were suitable to differentiate samples originating from 9 out of 11 manufacturers. Analytical fingerprints associated with chemometrics were demonstrated to be a valuable methodology to discriminate manufacturers of omeprazole and omeprazole magnesium APIs and detect future substandard and falsified APIs.
Collapse
Affiliation(s)
- H Rebiere
- French National Agency for Medicines and Health Products Safety, ANSM, Laboratory Controls Division, 635 Rue de la Garenne, 34740 Vendargues, France.
| | - Y Grange
- French National Agency for Medicines and Health Products Safety, ANSM, Laboratory Controls Division, 635 Rue de la Garenne, 34740 Vendargues, France; Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France
| | - E Deconinck
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Sciensano, Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, J. Wytsmanstraat 14, B-1050 Brussels, Belgium
| | - P Courselle
- Sciensano, Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, J. Wytsmanstraat 14, B-1050 Brussels, Belgium
| | - J Acevska
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000 Skopje, Republic of North Macedonia
| | - K Brezovska
- Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000 Skopje, Republic of North Macedonia
| | - J Maurin
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; National Medicines Institute, Falsified Medicines and Medical Devices Department, 30/34 Chelmska str., 00-725 Warsaw, Poland
| | - T Rundlöf
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Swedish Medical Products Agency, Laboratory, Box 26, Dag Hammarskjölds väg 42, SE-751 03 Uppsala, Sweden
| | - M J Portela
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Infarmed - National Authority of Medicines and Health Products, I.P., Parque de Saúde de Lisboa - Avenida do Brasil 53, 1749-004 Lisboa, Portugal
| | - L S Olsen
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Danish Medicines Agency, Medicines Control and Inspection Division, Axel Heides Gade 1, 2300 Copenhagen S, Denmark
| | - C Offerlé
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France
| | - M Bertrand
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France
| |
Collapse
|
3
|
Deconinck E, Courselle P, Raimondo M, Grange Y, Rebière H, Mihailova A, Bøyum O, Maurin JK, Pioruńska-Sędłak K, Olsen LS, Acevska J, Brezovska K, Rundlöf T, Portela MJ, Bertrand M. GEONs API fingerprint project: Selection of analytical techniques for clustering of sildenafil citrate API samples. Talanta 2021; 239:123123. [PMID: 34942486 DOI: 10.1016/j.talanta.2021.123123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 11/25/2021] [Accepted: 12/01/2021] [Indexed: 11/19/2022]
Abstract
Through its Active Pharmaceutical Ingredient Working Group (API-WG) the General European Official Medicines Control Laboratory (OMCL) Network (GEON), co-ordinated by the European Directorate for the Quality of Medicines & HealthCare (EDQM), regularly organises market surveillance studies for specific APIs for conformity to their monograph in the European Pharmacopoeia. During the past years some studies were combined with a fingerprint study of the APIs. The idea is to obtain a fingerprint for each manufacturer of the API under investigation, allowing the OMCL network to identify future samples as well as to detect substandard and falsified APIs. This paper reports the results of the latest fingerprint study, organised on sildenafil citrate API samples. Seventy-nine samples from 14 different manufacturers were collected throughout the Network. Fingerprint data was collected through Mid-Infrared spectroscopy, Raman spectroscopy, liquid chromatography for related substances, gas chromatography for residual solvents, X-ray diffraction and Nuclear Magnetic Resonance (NMR) spectroscopy. Chemometrics applied to the collected data showed that all manufacturers could be discriminated based on the data of only three of these tests, i.e. gas chromatography for residual solvents, X-ray diffraction and proton NMR. Suspicious API samples for sildenafil citrate will therefore be analysed in the future with the selected techniques in order to link the sample to a manufacturer or demonstrate the absence of such link. If the sample cannot be attributed to one of the manufacturers, further analysis and research on provenance and identity will be required. Of course, if the suspected sample claims to originate from one of the manufacturers included in the study, analysis can be limited to the test distinguishing this manufacturer.
Collapse
Affiliation(s)
- E Deconinck
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050, Brussels, Belgium.
| | - P Courselle
- Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050, Brussels, Belgium
| | - M Raimondo
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, Viale Regina Elena 299, 00161, Rome, Italy
| | - Y Grange
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; French National Agency for Medicines and Health Products Safety, Laboratory Controls Division, 635 Rue de la Garenne, 34740, Vendargues, France
| | - H Rebière
- French National Agency for Medicines and Health Products Safety, Laboratory Controls Division, 635 Rue de la Garenne, 34740, Vendargues, France
| | - A Mihailova
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - O Bøyum
- Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - J K Maurin
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; National Medicines Institute, 30/34 Chelmska Str., 00-725, Warsaw, Poland
| | - K Pioruńska-Sędłak
- National Medicines Institute, 30/34 Chelmska Str., 00-725, Warsaw, Poland
| | - L Stengelshøj Olsen
- Danish Medicines Agency, Medicines Control and Inspection Division, Axel Heides Gade 1, 2300, Copenhagen S, Denmark
| | - J Acevska
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Center for Drug Quality Control, Institute of Applied Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, University Ss.Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North-Macedonia
| | - K Brezovska
- Center for Drug Quality Control, Institute of Applied Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, University Ss.Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North-Macedonia
| | - T Rundlöf
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Swedish Medical Products Agency, Laboratory, Box 26, Dag Hammarskjölds Väg 42, SE-751 03, Uppsala, Sweden
| | - M J Portela
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; INFARMED, Autoridade Nacional Do Medicamento e Produtos de Saúde, I.P. Parque de Saúde de Lisboa, Avenida Do Brasil, 531749-004, Lisboa, Portugal
| | - M Bertrand
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France
| |
Collapse
|
4
|
Cvetkovikj I, Stefkov G, Acevska J, Stanoeva JP, Karapandzova M, Stefova M, Dimitrovska A, Kulevanova S. Polyphenolic characterization and chromatographic methods for fast assessment of culinary Salvia species from South East Europe. J Chromatogr A 2013; 1282:38-45. [PMID: 23415138 DOI: 10.1016/j.chroma.2012.12.068] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Revised: 12/20/2012] [Accepted: 12/23/2012] [Indexed: 11/17/2022]
Abstract
Although the knowledge and use of several Salvia species (Salvia officinalis, Salvia fruticosa, and Salvia pomifera) can be dated back to Greek Era and have a long history of culinary and effective medicinal use, still there is a remarkable interest concerning their chemistry and especially the polyphenolic composition. Despite the demand in the food and pharmaceutical industry for methods for fast quality assessment of the herbs and spices, even now there are no official requirements for the minimum content of polyphenols in sage covered by current regulations neither the European Pharmacopoeia monographs nor the ISO 11165 standard. In this work a rapid analytical method for extraction, characterization and quantification of the major polyphenolic constituents in Sage was developed. Various extractions (infusion - IE; ultrasound-assisted extraction - USE and microwave-assisted extraction - MWE) were performed and evaluated for their effectiveness. Along with the optimization of the mass-detector and chromatographic parameters, the applicability of three different reverse C18 stationary phases (extra-density bonded, core-shell technology and monolith column) for polyphenolics characterization was evaluated. A comprehensive overview of the very variable polyphenolic composition of 118 different plant samples of 68 populations of wild growing culinary Salvia species (S. officinalis: 101; S. fruticosa: 15; S. pomifera: 2) collected from South East Europe (SEE) was performed using HPLC-DAD-ESI-MS(n) and more than 50 different compounds were identified and quantified. With this work the knowledge about polyphenols of culinary Sage was expanded thus the possibility for gaining an insight into the chemodiversity of culinary Salvia species in South East Europe was unlocked.
Collapse
Affiliation(s)
- I Cvetkovikj
- Institute of Pharmacognosy, Faculty of Pharmacy, Ss. Cyril and Methodius University, Skopje, Macedonia.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Acevska J, Stefkov G, Petkovska R, Kulevanova S, Dimitrovska A. Chemometric approach for development, optimization, and validation of different chromatographic methods for separation of opium alkaloids. Anal Bioanal Chem 2012; 403:1117-29. [PMID: 22318699 DOI: 10.1007/s00216-012-5716-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2011] [Revised: 12/15/2011] [Accepted: 01/05/2012] [Indexed: 11/30/2022]
Abstract
The excessive and continuously growing interest in the simultaneous determination of poppy alkaloids imposes the development and optimization of convenient high-throughput methods for the assessment of the qualitative and quantitative profile of alkaloids in poppy straw. Systematic optimization of two chromatographic methods (gas chromatography (GC)/flame ionization detector (FID)/mass spectrometry (MS) and reversed-phase (RP)-high-performance liquid chromatography (HPLC)/diode array detector (DAD)) for the separation of alkaloids from Papaver somniferum L. (Papaveraceae) was carried out. The effects of various conditions on the predefined chromatographic descriptors were investigated using chemometrics. A full factorial linear design of experiments for determining the relationship between chromatographic conditions and the retention behavior of the analytes was used. Central composite circumscribed design was utilized for the final method optimization. By conducting the optimization of the methods in very rational manner, a great deal of excessive and unproductive laboratory research work was avoided. The developed chromatographic methods were validated and compared in line with the resolving power, sensitivity, accuracy, speed, cost, ecological aspects, and compatibility with the poppy straw extraction procedure. The separation of the opium alkaloids using the GC/FID/MS method was achieved within 10 min, avoiding any derivatization step. This method has a stronger resolving power, shorter analysis time, better cost/effectiveness factor than the RP-HPLC/DAD method and is in line with the "green trend" of the analysis. The RP-HPLC/DAD method on the other hand displayed better sensitivity for all tested alkaloids. The proposed methods provide both fast screening and an accurate content assessment of the six alkaloids in the poppy samples obtained from the selection program of Papaver strains.
Collapse
Affiliation(s)
- J Acevska
- Institute of Applied Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of Macedonia.
| | | | | | | | | |
Collapse
|